The legal complaint targets a period between January 14, 2025, and May 6, 2026, alleging that Zoetis executives misled shareholders regarding the company's core product performance. Plaintiffs contend that the firm failed to disclose that demand for Librela, a canine pain treatment, stalled after FDA safety warnings emerged concerning neurological complications.
Beyond these safety concerns, the lawsuit points to competitive pressures eroding the company's market dominance. Allegations suggest that Simparica Trio lost significant ground to lower-priced alternatives, while dermatology staples Apoquel and Cytopoint faced similar share displacement from newer rival treatments. Investors seeking to participate in the case or inquire about their rights can contact the Law Offices of Howard G. Smith at 215-638-4847 or via their website.
Comments (0)
No comments yet. Be the first!